Tevimbra® (tislelizumab-jsgr)
for Gastric Cancer Stomach Cancer
Tevimbra (tislelizumab-jsgr) is used to treat adults with certain types of esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that has spread or cannot be surgically removed. It works by blocking PD-1, a protein on T cells that prevents them from attacking healthy cells. Cancer cells use PD-1 to evade immune response, but by blocking PD-1, Tevimbra allows T cells to recognize and attack cancer cells more effectively.
